Salvato in:
| Autori principali: | , , , , , , , , , , |
|---|---|
| Natura: | Artículo Open Access |
| Pubblicazione: |
Wiley
2025
|
| Soggetti: | |
| Accesso online: | https://onlinelibrary.wiley.com/doi/10.1002/ijc.35513 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Sommario:
- Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study Muchandifunga Trust Muchadeyi Shuang Hao Karla Hernandez‐Villafuerte Shah Alam Khan Nikolaus Becker Agne Krilaviciute Petra Seibold Roman Gulati Peter Albers Michael Schlander Mark Clements International Journal of Cancer AbstractProstate cancer (PCa) represents a significant public health challenge in Germany, with increasing incidence and economic impact. This study assessed the cost‐effectiveness of 10 screening strategies: prostate‐specific antigen‐based risk‐adaptive screening (PSA‐RAS), with or without magnetic resonance imaging (MRI), in men starting at age 45 or 50 and stopping at 60 or 70, digital rectal examination (DRE) for ages 45–75 years, and no screening. Using a well calibrated microsimulation model (Swedish Prostata) from a statutory health insurance perspective, lifetime outcomes were evaluated, including cancer incidence, mortality, overdiagnosis, biopsies, life‐years, and quality‐adjusted life‐years (QALYs) discounted annually at 3%. Cost and utility inputs were derived from the German diagnostic‐related group schedule, fee‐for‐service catalogues, literature, and expert opinion. DRE‐only was the least cost‐effective, yielding high biopsy and overdiagnosis rates with minimal QALY gains. PSA‐RAS reduced overdiagnosis and biopsy rates, with PSA‐RAS (50–60 years) without MRI emerging as the most cost‐efficient strategy, saving approximately €1.2 million per 100,000 men compared with no screening. Extending the PSA‐RAS to 70 years improved its effectiveness in terms of QALYs. PSA‐RAS (50–70) with MRI could become cost‐effective at an increasing willingness to pay threshold or decreasing MRI cost. This study suggests the potential of PSA‐RAS to improve PCa screening in Germany. Incorporating MRI, reducing MRI cost within the screening setting, and extending screening to 70 to align with EU recommendations could improve the cost‐effectiveness of PSA‐RAS with MRI. Future research should explore the integration of MRI with ancillary tests, such as 4K‐score or risk calculators, to reduce MRI use and associated costs. 10.1002/ijc.35513 http://creativecommons.org/licenses/by/4.0/